Clinical Trial Update: TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating TAS-102 in combination with ramucirumab for advanced, refractory gastric or gastroesophageal junction adenocarcinoma has completed, wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Ramucirumab (ramucirumab)
• TAS-102 (trifluridine/tipiracil)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2023-03-15